BioSenic S.A. (BIOS.BR)
BioSenic S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mont-Saint-Guibert, BE. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1.3M. Its beta of -1.61 implies it has historically moved less than the broad market.
BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
BioSenic S.A. is most often compared with the following Healthcare names: